(YMAB)

SERB Pharmaceuticals has successfully acquired Y-mAbs Therapeutics for $8.60 per share, strengthening its rare oncology portfolio with the addition of Danyelza®, a treatment for pediatric neuroblastoma.

Law firm Brodsky & Smith is investigating potential breaches of fiduciary duties by boards of several companies during recent merger and acquisition transactions, focusing on whether shareholders are receiving fair value.

Y-mAbs Therapeutics reported Q2 2025 results with revenue exceeding expectations but declining 14% year-over-year, primarily due to lower DANYELZA product sales. The company is being acquired by SERB Pharmaceuticals and is focusing on expanding its cancer therapy portfolio.

YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of -25% and 9.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?